In the US/EU combined market, the treatment-experienced and the diagnosed treatment-naive markets are roughly equal in size, so you can get market-share figures with some simple arithmetic.
However, I don't concur with your premise that GILD will take 90% of the the treatment-naive market.
Market Data 
Markets 
AI
